hs-CRP marker predicts long-term risk and benefits of therapy
This article was originally published in Clinica
Executive Summary
Measuring levels of the inflammatory marker hs-CRP before patients with atherosclerosis undergo percutaneous interventions (PCI) could help predict their outcomes and identify those who would benefit the most from long-term clopidogrel and aspirin therapy.